BridgeBio Pharma Inc (NASDAQ: BBIO) stock fell -0.03% on Monday to $29.24 against a previous-day closing price of $29.25. With 0.9 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.57 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $30.08 whereas the lowest price it dropped to was $28.79. The 52-week range on BBIO shows that it touched its highest point at $36.36 and its lowest point at $6.64 during that stretch. It currently has a 1-year price target of $46.20. Beta for the stock currently stands at 1.01.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BBIO was up-trending over the past week, with a rise of 6.25%, but this was up by 19.01% over a month. Three-month performance surged to 3.18% while six-month performance rose 113.27%. The stock gained 203.01% in the past year, while it has gained 283.73% so far this year. A look at the trailing 12-month EPS for BBIO yields -3.91 with Next year EPS estimates of -3.23. For the next quarter, that number is -0.85. This implies an EPS growth rate of -13.54% for this year and 12.83% for next year.
Float and Shares Shorts:
At present, 150.63 million BBIO shares are outstanding with a float of 124.95 million shares on hand for trading. On Oct 30, 2023, short shares totaled 15.97 million, which was 9.18% higher than short shares on Sep 28, 2023. In addition to Dr. Neil Kumar Ph.D. as the firm’s Co-Founder, President, CEO & Director, Dr. Charles J. Homcy M.D. serves as its Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director.
Institutional Ownership:
Through their ownership of 95.46% of BBIO’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 63.84% of BBIO, in contrast to 53.80% held by mutual funds. Shares owned by individuals account for 24.93%. As the largest shareholder in BBIO with 15.46% of the stake, Viking Global Investors LP holds 25,120,991 shares worth 25,120,991. A second-largest stockholder of BBIO, The Vanguard Group, Inc., holds 10,996,443 shares, controlling over 6.77% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in BBIO, holding 7,909,265 shares or 4.87% stake. With a 2.20% stake in BBIO, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 3,568,230 shares are owned by the mutual fund manager. The Vanguard Small Cap Index Fund, which owns about 1.81% of BBIO stock, is the second-largest Mutual Fund holder. It holds 2,934,508 shares valued at 76.41 million. SPDR S&P Biotech ETF holds 1.68% of the stake in BBIO, owning 2,724,576 shares worth 70.95 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BBIO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BBIO analysts setting a high price target of $60.00 and a low target of $28.00, the average target price over the next 12 months is $46.20. Based on these targets, BBIO could surge 105.2% to reach the target high and fall by -4.24% to reach the target low. Reaching the average price target will result in a growth of 58.0% from current levels.
Summary of Insider Activity:
Insiders traded BBIO stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 2,500 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 30 over the past year. The total number of shares bought during that period was 405,297 while 3,003,962 shares were sold.
